Eli Lilly, Amylyx, Johnson & Johnson

Sign up for the biotech newsletter to stay updated on the latest developments in science and politics driving the biotech industry. Recent news includes Eli Lilly’s Zepbound showing efficacy in treating obstructive sleep apnea, Amylyx’s disappointing data leading to the withdrawal of their ALS drug, and potential market growth for psychedelics. Other updates include Sage Therapeutics’ failed cognitive improvement drug in Parkinson’s disease, Brainstorm Cell Therapeutics’ CEO departure, and Future Pak’s offer to acquire Vanda Pharmaceuticals. Additionally, Cullinan Therapeutics is expanding into autoimmune disease, and Pfizer veteran Uwe Schoenbeck joins venture firm Canaan as a partner.

Source link

error: Content is protected !!